The investment round was led by Ventura Capital and will accelerate international deployment of the company's diagnostic platform.
"The game-changing nature of our innovation has created an extraordinary commercial opportunity within next-generation medical diagnostics, and the global investor community is very excited by the transformative potential of a rapid, gold-standard RT-PCR testing platform that can screen for multiple viruses simultaneously. We are delighted to have completed this successful fund-raise which will allow us to dramatically speed our plans for worldwide availability, particularly in the US, Japan, Europe, and other key territories where interest is extremely high."
The Series B round was led by the Blue Venture Fund to accelerate the deployment of artificial intelligence in echocardiography.
"Echocardiograms uploaded to the cloud and analyzed by artificial intelligence are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy,"
The funding round was led by DSW Ventures with backing from Mercia and SFC Capital.
"I am delighted to welcome DSW Ventures and Mercia on board at this exciting time for the company. The raise was oversubscribed by 60%, helped by the continuing support of SFC Capital and our angel investors. This puts us in a strong position as we move into the next phase of taking our products to market."
The Series D round was led by Segulah Medical Acceleration, Angelus Venture Fund I, Alan Howard, and Pioneer Healthcare Partners to support commercial expansion.
"We believe that Signifier Medical Technologies has created the most disruptive, non-invasive treatment for OSA that the market has seen in the past 20 years."
The oversubscribed round was backed by Consilience Ventures, SOSV, and Catapult Ventures to support the development of the GRACE device.
"This investment is a vote of confidence in QV Bioelectronics from sector-expert investors. The funds raised will fuel the next phase of development of the GRACE device, allowing the size of the QV Bioelectronics team to grow in the process. This will take our innovative electric field therapy technology a few steps closer towards the clinic."
